New treatments for stimulant use disorders
PTPRD phosphatase inhibitors for stimulant use disorders
This study is exploring a new type of medication that could help people struggling with stimulant addiction by targeting a specific protein in the brain, aiming to reduce cravings and improve treatment results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10653070 on NIH RePORTER |
What this research studies
This research investigates the potential of PTPRD phosphatase inhibitors as a novel treatment for stimulant use disorders, which affect millions of Americans. The study aims to develop medications that target the PTPRD protein, which has been linked to the vulnerability to stimulant addiction and the brain's reward response to these substances. By utilizing both human genomic data and mouse models, researchers will assess the effectiveness of these inhibitors in reducing stimulant cravings and improving treatment outcomes for individuals struggling with addiction. The approach combines pharmacological development with genetic insights to create a targeted therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with stimulant use disorders, such as those addicted to cocaine or amphetamines.
Not a fit: Patients who do not have stimulant use disorders or those who are not seeking treatment for addiction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the first FDA-approved medication specifically designed to help individuals overcome stimulant use disorders.
How similar studies have performed: While the approach of targeting PTPRD is novel, previous research has shown promise in developing medications for addiction based on genetic and pharmacological insights.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Uhl, George Richard — University of Maryland Baltimore
- Study coordinator: Uhl, George Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.